SLFN12 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16156956	1.00	1/20
SCHEMBL16156971	1.00	1/20
SCHEMBL29491012	1.00	1/20
SCHEMBL29491026	1.00	1/20
SCHEMBL29609389	1.00	1/20
SCHEMBL10333380	0.82	1/20
SCHEMBL17446927	0.79	1/20
SCHEMBL17446945	0.79	1/20
SCHEMBL10333665	0.78	1/20
SCHEMBL10699653	0.76	1/20
SCHEMBL16157016	0.72	1/20
SCHEMBL17446972	0.72	1/20
SCHEMBL7321517	0.71	1/20
SCHEMBL10333846	0.69	1/20
SCHEMBL7275175	0.69	1/20
SCHEMBL2015885	0.67	1/20
SCHEMBL5332160	0.67	1/20
SCHEMBL10333008	0.67	1/20
SCHEMBL10333516	0.67	1/20
SCHEMBL10333605	0.67	1/20

Clinical trials — most relevant to SLFN12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma	PHASE2	ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100	PHASE1/PHASE2	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects	PHASE1	COMPLETED
Biocollection in MyeloDysplastic Syndrome (P-MDS)	nan	RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Genetic Investigation of Cancer Predisposition	nan	NOT_YET_RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank	nan	COMPLETED
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia	nan	RECRUITING
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae	nan	ACTIVE_NOT_RECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
Uncovering the Etiologies of Non-immune Hydrops Fetalis	nan	ENROLLING_BY_INVITATION
Impact of Elastin Mediated Vascular Stiffness on End Organs	nan	COMPLETED
Shwachman Diamond Syndrome Registry and Study	nan	RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
Genetic Linkage Studies of Stuttering	nan	COMPLETED
Mechanisms of Cell Death in Spinal Muscular Atrophy	nan	COMPLETED
Natural History Study of Smith-Magenis Syndrome	nan	ACTIVE_NOT_RECRUITING
Study of Constitutional Platelet Disease	nan	UNKNOWN
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLFN12 binder may also engage these)

Protein	Name	Similarity
Q5RCZ8	—	1.000	Q5RCZ8 →
B1ARD8	—	0.995	B1ARD8 →
Q6IEE8	—	0.994	Q6IEE8 →
Q7Z7L1	—	0.993	Q7Z7L1 →
Q5U311	—	0.991	Q5U311 →
B1ARD6	—	0.991	B1ARD6 →
G1SRW8	—	0.991	G1SRW8 →
Q68D06	—	0.989	Q68D06 →
V9GXG1	—	0.989	V9GXG1 →
Q8CBA2	—	0.988	Q8CBA2 →
Q9Z0I7	—	0.988	Q9Z0I7 →
Q08AF3	—	0.987	Q08AF3 →
P0C7P3	—	0.987	P0C7P3 →
Q5K651	—	0.985	Q5K651 →
Q9Z0I6	—	0.984	Q9Z0I6 →
Q8IVG5	—	0.984	Q8IVG5 →
Q69Z37	—	0.980	Q69Z37 →
Q6P3V7	—	0.979	Q6P3V7 →
Q5H9U9	—	0.978	Q5H9U9 →
Q8SPH9	—	0.977	Q8SPH9 →
Q96PZ2	—	0.977	Q96PZ2 →
Q6AYC2	—	0.977	Q6AYC2 →
PARP9	Protein mono-ADP-ribosyltransferase PARP9	0.976	landscape →
Q6ZSC3	—	0.976	Q6ZSC3 →
Q9JIP3	—	0.976	Q9JIP3 →
Q8CAS9	—	0.976	Q8CAS9 →
P41218	—	0.975	P41218 →
Q62611	—	0.975	Q62611 →
Q91VJ1	—	0.975	Q91VJ1 →
Q2TB18	—	0.974	Q2TB18 →